BeOne Medicines Ltd. (BVMF:B1ME34)

Market Cap	186.88B
Revenue (ttm)	24.86B
Net Income (ttm)	-967.93M
Shares Out	n/a
EPS (ttm)	-9.06
PE Ratio	n/a
Forward PE	106.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	41
Open	67.55
Previous Close	67.55
Day's Range	67.55 - 67.55
52-Week Range	41.36 - 69.65
Beta	n/a
RSI	71.39
Earnings Date	Aug 29, 2025

About BeOne Medicines

BeOne Medicines Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Employees: 11,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: B1ME34

Financial Performance

In 2024, BeOne Medicines's revenue was $3.81 billion, an increase of 54.96% compared to the previous year's $2.46 billion. Losses were -$644.79 million, -26.87% less than in 2023.

Financial numbers in USD